AbbVie Inc.

About AbbVie Inc.

AbbVie is a global pharmaceutical company that discovers, develops and sells prescription medicines to patients through healthcare providers, payers and distribution channels. Its portfolio spans immunology, neuroscience, oncology, aesthetics, eye care and other specialty areas; the supplied evidence identifies immunology as a major growth franchise and highlights neuroscience expansion, depression treatment and phase 3 pipeline wins. AbbVie makes money primarily from product sales rather than tokenized securities or financial services. It generated $61.2 billion of revenue and $4.2 billion of net income in fiscal 2025, compared with $56.3 billion and $4.3 billion, respectively, in fiscal 2024.

Notable Price Movement

1. Sep 14-18$263.962.66%

   AbbVie rose 2.07% over the week, from $256.46 to $261.77, extending a recovery that had already carried the stock from $248.78 on September 8 to $257.12 on September 11. The decisive move came on September 14, when shares gained $4.65, or 1.81%, despite Zacks reporting that the broader market declined. No supplied evidence identifies a company-specific announcement, earnings release, guidance change, or analyst action during the week that explains the advance. Instead, trading appears to have reflected continued investor interest in AbbVie’s growth portfolio, including immunology, neuroscience and pipeline developments, alongside valuation support cited by several articles. The stock therefore moved higher against a weaker market, without a clearly documented weekly catalyst.

   28 sources
2. Sep 7-11$257.120.26%

   AbbVie fell $7.64, or 2.98%, from $256.42 to $248.78 over the period. The stock initially advanced, gaining to $259.99 on September 1 and $261.72 on September 2, before reversing over the next two sessions and giving back the entire rise by September 4. It then dropped another 2.99% to $248.78 in the latest session, on volume of 5.57 million shares versus 4.73 million previously. The supplied evidence does not identify a company-specific announcement that explains the reversal. Investor discussion instead centered on valuation, Skyrizi reliance, dividend support and a positive migraine-trial result, while the latest decline was reported as larger than the market's move without a stated AbbVie catalyst.

   28 sources
3. Aug 31 - Sep 4$256.460.38%

   AbbVie rose $2.06, or 0.80%, over the reported week, moving from $258.15 to $260.21. The stock initially lagged after closing at $256.42 on Monday, then gained 1.4% Tuesday and another 0.7% Wednesday before giving back $1.51, or 0.6%, Thursday. The strongest company-specific support was positive Phase 3 CERVINO data for investigational etentamig in relapsed or refractory multiple myeloma, which strengthened the oncology and pipeline narrative. Coverage also focused on AbbVie’s FY2026 earnings guidance, while the completed $10.9 billion Apogee Therapeutics acquisition reinforced its immunology pipeline. The supplied evidence does not identify a broader market catalyst or quantify the guidance.

   28 sources
4. Aug 24-28$255.483.58%

   AbbVie fell $3.68, or 1.41%, over the week, from $261.83 to $258.15. The stock initially resisted the broader weakness implied by no specific market catalyst in the supplied evidence, closing at $264.52 on Monday and $265.79 on Tuesday. It then reversed, losing $2.89 on Wednesday and another $4.75 on Thursday. The principal company-specific developments were AbbVie’s European regulatory submission for subcutaneous Skyrizi induction in Crohn’s disease, a potentially favorable convenience and access catalyst, and evidence that second-quarter oncology sales fell 2.4% as Imbruvica declined, despite support from Venclexta and newer medicines. The week’s late selling outweighed the earlier Skyrizi-related optimism.

   25 sources
5. Aug 17-21$264.966.21%

   The stock rose 4.39%, from $250.82 to $261.83, with nearly all of the advance concentrated in Tuesday and Wednesday. ABBV gained from $250.33 to $258.92 on Aug. 18, then climbed to $265.97 on Aug. 19 as trading volume increased to 5.54 million shares, before giving back $4.14, or 1.56%, on Aug. 20. The supplied evidence does not identify a material company-specific announcement, earnings release, guidance change, or clinical update during the week. Articles focused mainly on the rally, valuation, financing, insider activity, and institutional holdings. The stock therefore moved without an explicitly documented company catalyst; broader market context is not provided.

   28 sources
6. Aug 10-14$249.461.39%

   AbbVie rose $2.87, or 1.17%, from $245.10 to $247.97 over the week. Trading was volatile rather than steadily directional: the stock fell to $243.80 on Tuesday, rallied to $246.20 Wednesday, retreated to $243.87 Thursday, then recovered on Friday and added a further $1.93 on Monday. The supplied evidence does not identify a company-specific announcement that clearly drove the daily moves. Investor attention around the period focused on AbbVie’s lifted 2026 guidance, strong second-quarter growth, potential neuroscience-drug momentum, and Botox moving closer to a fifth indication, but the timing and market impact of those items are not established. The shares therefore appear to have moved mainly on trading momentum and broader market factors not specified in the evidence.

   28 sources
7. Aug 3-7$246.041.95%

   AbbVie fell $19.40, or 7.37%, from $263.20 to $243.80 over the measured week. Shares were essentially flat through July 29 before declining for four consecutive sessions, including heavier volume on August 3 and 4. The main catalyst was the second-quarter update: AbbVie beat earnings and revenue expectations and raised full-year revenue guidance by $300 million, but cut its 2026 EPS outlook because of the Apogee acquisition, which also increases research and development spending. Strong Skyrizi, Rinvoq, immunology and neuroscience growth therefore failed to offset dilution concerns. Regulatory news was constructive but secondary, with Canadian reimbursement support for Ubrelvy and FDA review of a Botox Cosmetic application.

   20 sources

Stories & Analysis

AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?The Motley Fool · 14h agoWhat Is AbbVie (ABBV) Stock and ABBVx Tokenized Stock?Pintu · 2d agoAbbVie’s Dividend Growth Remains Solid Despite a Moderate YieldInsider Monkey · 2d agoAbbVie Reports Real-World Data For VRAYLAR In Depressive DisorderRTTNews · 2d agoAbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · 2d agoAbbVie’s depression drug improved mood and daily life in real-world studiesStock Titan · 2d agoAbbVie (ABBV) Could Be 4% Undervalued After Phase 3 Trial Winssimplywall.st · 3d agoAbbVie To Present Positive Phase 3 Etentamig Data At IMS 2026RTTNews · 3d ago